Opinion|Videos|August 27, 2026
Key Takeaways and Future Directions in EGFR-Mutated Advanced NSCLC
Author(s)Sandip Patel, MD, Amy Cummings, MD, PhD,
In closing, the faculty offer their top takeaways from the discussion and look ahead at how they anticipate the treatment landscape for EGFR-mutated advanced NSCLC evolving.
Advertisement
In closing, the faculty offer their top takeaways from the discussion and look ahead at how they anticipate the treatment landscape for EGFR-mutated advanced NSCLC evolving.
Advertisement
Related to this article
Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
3
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
4
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
5